New drug shows promise in keeping HBV-Linked lymphoma at bay
NCT ID NCT04661943
First seen Mar 25, 2026 · Last updated May 02, 2026 · Updated 2 times
Summary
This study tested the drug chidamide as a maintenance therapy for 30 people with hepatitis B virus (HBV)-positive diffuse large B-cell lymphoma who had already achieved complete remission after chemotherapy. The goal was to see if chidamide could help keep the cancer from returning. The trial was a single-arm, open-label phase 2 study, meaning all participants received the drug and knew they were getting it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.